Harvoni and rival hep C drugs look set for approval in England – but NHS England may have the last word on controlling costs, finds Andrew McConaghie. Patients in England with hepatitis C (HCV) will ...
NICE has given the green light to three new hepatitis C treatments, but has specified precisely which patients can receive which drugs, based on the patient's genotypes, and the progression of their ...
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback